GlaxoSmithKline 's Avandia was the best-selling diabetes drug in the world until Steven Nissen of the Cleveland Clinic published an analysis of clinical trial data that showed a heightened risk of heart attacks, strokes and cardiovascular death for patients on the drug.

FORBES: Magazine Article